1. Home
  2. MBIN vs ANAB Comparison

MBIN vs ANAB Comparison

Compare MBIN & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Merchants Bancorp

MBIN

Merchants Bancorp

HOLD

Current Price

$34.94

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$47.66

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBIN
ANAB
Founded
1990
2005
Country
United States
United States
Employees
663
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.4B
IPO Year
2017
2017

Fundamental Metrics

Financial Performance
Metric
MBIN
ANAB
Price
$34.94
$47.66
Analyst Decision
Buy
Buy
Analyst Count
3
12
Target Price
$39.67
$60.18
AVG Volume (30 Days)
136.2K
499.2K
Earning Date
01-28-2026
02-26-2026
Dividend Yield
1.13%
N/A
EPS Growth
N/A
N/A
EPS
4.34
N/A
Revenue
$597,247,000.00
$169,467,000.00
Revenue This Year
$5.17
$135.51
Revenue Next Year
$7.24
N/A
P/E Ratio
$8.13
N/A
Revenue Growth
N/A
196.42
52 Week Low
$27.25
$12.21
52 Week High
$43.82
$52.47

Technical Indicators

Market Signals
Indicator
MBIN
ANAB
Relative Strength Index (RSI) 50.54 53.20
Support Level $34.51 $46.06
Resistance Level $36.82 $50.00
Average True Range (ATR) 0.97 3.02
MACD -0.05 -0.05
Stochastic Oscillator 28.77 64.38

Price Performance

Historical Comparison
MBIN
ANAB

About MBIN Merchants Bancorp

Merchants Bancorp is a United States based bank holding company. It operates multiple lines of business focusing on FHA (Federal Housing Administration) multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. The business segments of the company are: Multi-family Mortgage Banking which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing segment which funds agency-eligible residential loans as well as commercial loans to nondepository financial institutions; and the Banking segment, which generates maximum revenue, and provides various financial products and services to consumers and businesses.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: